摘要
评价重组人干扰素α2b体外广谱抗呼吸道病毒的药效。本实验在细胞水平采用实时荧光定量RT-PCR法检测重组人干扰素α2b抗A型流感病毒药效。采用细胞病变(CPE)法检测重组人干扰素α2b抗B型流感病毒、副流感病毒(HPIV)、呼吸道合胞病毒(RSV)和冠状病毒的药效。结果表明,3次实验中,重组人干扰素α2b对副流感病毒的平均治疗指数为1 476.63、对呼吸道合胞病毒的平均治疗指数为141.37、对冠状病毒的平均治疗指数大于2 820.76,药效均强于利巴韦林(RBV)。重组人干扰素α2b对不同A型流感病毒的RNA有很强的抑制作用,药效强于对照药物。重组人干扰素α2b对B型流感病毒的治疗指数为2.74,治疗效果一般。结果提示,重组人干扰素α2b在体外具有很好的广谱抗呼吸道病毒的活性,且毒性低,治疗指数高,有望成为临床治疗呼吸道病毒感染的特效药,更好的服务于呼吸道病毒感染的预防和治疗。
This study is to investigate the effect of recombinant human interferon alpha 2b against broad-spectrum respiratory viruses in vitro. At the cellular level,the effect of the recombinant human interferon alpha 2b on influenza A virus was detected using real-time fluorescence quantitative RT-PCR. The effects of the recombinant human interferon alpha 2b on influenza B virus,parainfluenza virus,respiratory syncytial virus（RSV） and coronavirus were detected using cytopathic effect（CPE） method. In this study,the therapeutic index of recombinant human interferon alpha 2b anti-HPIV was 1476.63,the therapeutic index of recombinant human interferon alpha 2b anti-RSV was 141.37,the therapeutic index of recombinant human interferon alpha 2b anti-coronavirus was more than 2820.76,and the antiviral effect of recombinant human interferon alpha 2b was better than ribavirin（RBV）. Recombinant human interferon alpha 2b has a stronger inhibitory effect on different influenza A virus RNA than drug control. The therapeutic index of recombinant human interferon alpha 2b anti-influenza B virus was 2.74,with modest effect. Recombinant human interferon alpha 2b in vitro has broad spectrum antiviral activities,low toxicity and high therapeutic index. Recombinant human interferon alpha 2b is expected to become the efficient medicine in clinical against respiratory viruses,as well as provide better services for prevention and treatment of respiratory viruses＇ infections.
出处
《药学学报》
CAS
CSCD
北大核心
2014年第11期1547-1553,共7页
Acta Pharmaceutica Sinica
基金
综合性新药研究开发技术大平台“生物药效与药理学”研究(2012ZX09301-002-005)
“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项(2012ZX10004501-004-001)
